Literature DB >> 26837588

Combination therapies in oncology.

Rachel M Webster1.   

Abstract

Mesh：

Year:  2016        PMID： 26837588     DOI： 10.1038/nrd.2016.3

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  32 in total

Review 1.  Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.

Authors:  Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss
Journal:  Med Res Rev       Date:  2016-12-07       Impact factor: 12.944

2.  GBM Drug Bank-a new resource for glioblastoma drug discovery and informatics research.

Authors:  Fredrik Svensson; Bart Westerman; Thomas Würdinger; David Bailey
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

3.  Prediction of drug combination effects with a minimal set of experiments.

Authors:  Aleksandr Ianevski; Anil K Giri; Prson Gautam; Alexander Kononov; Swapnil Potdar; Jani Saarela; Krister Wennerberg; Tero Aittokallio
Journal:  Nat Mach Intell       Date:  2019-12-09

Review 4.  Drug combination therapy increases successful drug repositioning.

Authors:  Wei Sun; Philip E Sanderson; Wei Zheng
Journal:  Drug Discov Today       Date:  2016-05-27       Impact factor: 7.851

5.  Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer.

Authors:  Wenjing Ma; Xiaoping Zhao; Kaiying Wang; Jianjun Liu; Gang Huang
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

6.  A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

Authors:  Anna Ressa; Evert Bosdriesz; Joep de Ligt; Sara Mainardi; Gianluca Maddalo; Anirudh Prahallad; Myrthe Jager; Lisanne de la Fonteijne; Martin Fitzpatrick; Stijn Groten; A F Maarten Altelaar; René Bernards; Edwin Cuppen; Lodewyk Wessels; Albert J R Heck
Journal:  Mol Cell Proteomics       Date:  2018-07-03       Impact factor: 5.911

7.  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Authors:  Li Tan; Deepak Gurbani; Ellen L Weisberg; Douglas S Jones; Suman Rao; William D Singer; Faviola M Bernard; Samar Mowafy; Annie Jenney; Guangyan Du; Atsushi Nonami; James D Griffin; Douglas A Lauffenburger; Kenneth D Westover; Peter K Sorger; Nathanael S Gray
Journal:  Bioorg Med Chem       Date:  2016-12-07       Impact factor: 3.641

8.  Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.

Authors:  Weiwei Yu; Weiqiang Lu; Guoliang Chen; Feixiong Cheng; Hui Su; Yihua Chen; Mingyao Liu; Xiufeng Pang
Journal:  Br J Pharmacol       Date:  2017-08-24       Impact factor: 8.739

9.  Synchronous Chemoradiation Nanovesicles by X-Ray Triggered Cascade of Drug Release.

Authors:  Zijian Zhou; Alexander Chan; Zhantong Wang; Xiaolin Huang; Guocan Yu; Orit Jacobson; Sheng Wang; Yijing Liu; Lingling Shan; Yunlu Dai; Zheyu Shen; Lisen Lin; Wei Chen; Xiaoyuan Chen
Journal:  Angew Chem Int Ed Engl       Date:  2018-06-14       Impact factor: 15.336

10.  Hyaluronic Acid Grafted Nanoparticles of a Platinum(II)-Silicon(IV) Phthalocyanine Conjugate for Tumor and Mitochondria-Targeted Photodynamic Therapy in Red Light.

Authors:  Koushambi Mitra; Montserrat Samso; Charles E Lyons; Matthew C T Hartman
Journal:  J Mater Chem B       Date:  2018-10-24       Impact factor: 6.331
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.